Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Seattle Children's Hospital
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
Milton S. Hershey Medical Center
National Cancer Institute (NCI)
Baylor College of Medicine
Baylor College of Medicine
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Cellectar Biosciences, Inc.
St. Jude Children's Research Hospital
Ono Pharmaceutical Co., Ltd.
University of Florida
Children's National Research Institute
Baylor College of Medicine
University of California, San Francisco
Emory University
Eli Lilly and Company
C17 Council
Seattle Children's Hospital
St. Jude Children's Research Hospital
Dana-Farber Cancer Institute
Stanford University
Baylor College of Medicine
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
Medical College of Wisconsin
Seattle Children's Hospital
Seattle Children's Hospital
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Seattle Children's Hospital
Seattle Children's Hospital
Milton S. Hershey Medical Center
Baylor College of Medicine
St. Jude Children's Research Hospital
Baylor College of Medicine
Nationwide Children's Hospital